Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1324 |
Name | lung cancer |
Definition | A respiratory system cancer that is located_in the lung. |
Source | DiseaseOntology.org |
Alt Ids | DOID:13075 DOID:9881 DOID:1322 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01014598 | Phase I | Cisplatin | Cisplatin in Treating Patients With Lung Cancer | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01386580 | Phase Ib/II | 2B3-101 2B3-101 + Trastuzumab | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Completed | USA | FRA | BEL | 1 |
NCT01470209 | Phase I | Buparlisib + Everolimus | A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies | Completed | USA | 0 |
NCT01859026 | Phase I | Binimetinib + Erlotinib | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | Completed | USA | 0 |
NCT01935336 | Phase II | Ponatinib | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | Completed | USA | 0 |
NCT01999985 | Phase I | Afatinib + Dasatinib | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02047747 | Phase II | Dacomitinib | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Terminated | USA | 0 |
NCT02155465 | Phase Ib/II | Erlotinib + Ruxolitinib | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | Completed | USA | 0 |
NCT02241369 | Phase I | INO-3106 + INO-9012 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | Completed | USA | 0 |
NCT02264236 | Phase Ib/II | Montanide ISA 51 + P10s-PADRE | Vaccination of Advanced-Stage Lung Cancer Patients | Withdrawn | USA | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
NCT02429843 | Phase I | Carboplatin + Paclitaxel Bevacizumab Carotuximab | A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | Completed | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 24 |
NCT02675829 | Phase II | Ado-trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Recruiting | USA | 0 |
NCT02768337 | Phase Ib/II | Afatinib | Cambridge Brain Mets Trial 1 (CamBMT1) | Unknown status | 1 | |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | FRA | DEU | CAN | 5 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03373760 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | Completed | USA | 0 |
NCT03477162 | Phase 0 | Metformin | Metformin Pharmacology in Human Cancers: A Proof of Principle Study | Terminated | USA | 0 |
NCT03597009 | Phase Ib/II | Nivolumab + Talimogene laherparepvec | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | Terminated | USA | 0 |
NCT03719768 | Phase I | Avelumab | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Active, not recruiting | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT04085315 | Phase I | Alisertib + Osimertinib | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Recruiting | USA | 0 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | 2 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Recruiting | FRA | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients | Recruiting | USA | 0 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Recruiting | USA | ESP | DEU | 2 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04287868 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Active, not recruiting | USA | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | ESP | 1 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Recruiting | 1 | |
NCT05060432 | Phase Ib/II | EOS-448 + Pembrolizumab EOS-448 + EOS100850 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) | Recruiting | USA | FRA | BEL | 0 |
NCT05620342 | Phase I | iC9.GD2.CAR.IL-15 T-cells | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Not yet recruiting | USA | 0 |
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |